Conditions: Ovarian Neoplasms
Keywords: Advanced ovarian cancer BRCA1 protein BRCA2 protein Poly(ADP ribose) polymerases
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 97
Healthy volunteers: no

Brief summary:
The purpose of the study is to compare the efficacy and safety of 2 doses of drug AZD2281 against liposomal doxorubicin to see which is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and who have failed previous platinum therapy.

Detailed description:

Arms:
arm 1: AZD2281 Oral 200 mg BID arm 2: Liposomal Doxorubicin arm 3: AZD2281 Oral 400 mg BID

Interventions: intervention 1: AZD2281 intervention 2: Liposomal Doxorubicin intervention 3: AZD2281
Intervention descriptions: intervention 1: 400mg Oral twice daily intervention 2: 50mg/m2 Monthly Intravenous intervention 3: 200mg oral twice daily

Protocol document: